Intellia files first in-vivo CRISPR therapy with the FDA Phase 3 HAELO cut hereditary-angioedema attacks 87%; rolling BLA for lonvo-z opens the path to the first marketed in-body gene edit How Life Changes ·12 takes ·6月24日